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The two most common disorders of the nail are onychomycosis (fungal infections of the nail plate and/or 
bed) and psoriasis.  Onychomycosis is usually treated with oral antifungals, while psoriasis necessitates 
repeated monthly injections of corticosteroids into the nail folds.  Ideally, these diseases would be treated 
topically to eliminate the inherent side effects of the current treatments such as pain, systemic adverse 
events and drug interactions, and to increase patient compliance.  The effectiveness of topical therapy is, 
however, limited mainly by the very poor permeability of drugs in the nail plate.  So far, only a few ungual 
enhancers, such as N-acetyl cysteine, mercaptoethanol, N-(2-mercaptopropionyl) glycine, have been 
identified.   
 
The aim of this study was to investigate the potential of low-frequency ultrasound as a physical technique 
to enhance the ungual permeation of topically applied drugs.  
 
Bovine hoof membranes (thickness ≈ 150-200 µm) were used as a model for the nail plate and metformin 
was used as a model drug.  Low frequency ultrasound was applied to hoof membranes using a 13mm 
ultrasound probe placed at 1cm from the hoof membrane, via a coupling medium. A 50% intensity level (of 
the machine) was used for 1 min total sonication time, applied in a pulsatile manner (2 sec on – 2 sec off).  
Subsequently, the hoof membranes were removed from the sonication setup, disks were punched out and 
the membranes were sandwiched between donor and receptor compartments of modified Franz diffusion 
cells for permeation studies.  The drug concentration in the receptor phase was measured at time intervals 
using UV spectroscopy. 
 
Greater drug movement was found through ultrasound-treated hoof membranes (US) compared to control 
membranes (M) as shown in the Figure below.  The transport parameters of the model drug, metformin, are 
shown in the Table below.  Statistical analyses showed the flux and permeability coefficient were 
significantly different (P<0.05) for ultrasound-treated and control membranes.  These preliminary studies 
indicate the promise of low-frequency ultrasound as a physical ungual enhancer and the need for further 
investigations.  Optimisation of the ultrasound parameters – sonication time, intensity, duty cycle, probe 
shape, size and distance from the membrane – is expected to increase the enhancement of drug permeation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Control Ultrasound-treated 
Diffusion coefficient  (x 10
-4
 mm
2
/min) 1.4  (0.7) 1.1  (0.3)   
Partition coefficient 2.3  (1.6)        6.5 (3.0)  
Permeability coefficient ( x 10
-3
 mm/min) 1.3 (0.3)           3.4 (1.3)         * 
Lag time (min) 55.8 (36.7) 66.6 (41.0) 
Flux  ( x 10
-3 
g/mm2 per min) 2.6 (0.6)           6.8 (2.6)         * 
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